Sujet(s)
Varices oesophagiennes et gastriques , Hémorragie gastro-intestinale , Anastomose portosystémique intrahépatique par voie transjugulaire , Humains , Anastomose portosystémique intrahépatique par voie transjugulaire/effets indésirables , Hémorragie gastro-intestinale/étiologie , Varices oesophagiennes et gastriques/étiologie , Varices oesophagiennes et gastriques/chirurgie , Hypertension portale/complications , Hypertension portale/étiologie , Cirrhose du foie/complicationsRÉSUMÉ
OBJECTIVE: Aim: To evaluate the effectiveness of PSAE for secondary prevention of VB episodes in patients with chronic liver disease (CLD) and CSPH. PATIENTS AND METHODS: Materials and Methods: One hundred twenty patients (from 2008 to 2020) were submitted of PSAE as secondary prevention treatment. The results of the treatment of 27 patients between 2008 and 2012 (first period) were compared with those of 93 patients treated with PSAE since 2013 (second period), as procedure and management protocol were modificated. VB recurrence rate and mortality (related and non-related to bleeding episodes) were defined as study end-points in both groups at 12-months follow-up. RESULTS: Results: At 12-months follow-up, 11 (40,7 %) and 54 (58,1 %) patients in groups 1 and 2, respectively, were free from VBs (p=0,129). Overall mortality rate was significantly higher in group 1, as compared to group 2: 10 (37,0 %) versus 6 (6,4 %) patients, respectively (p<0,001), - due to higher frequency of fatal VB events (7 (26,0 %) vs. 3 (3,2 %) patients, respectively; p=0,001). CONCLUSION: Conclusions: PSAE is an effective treatment for secondary prevention of VB in patients with CLD and CSPS. The management protocol modification resulted in the decrease in overall mortality rate and mortality related to recurrent VB episodes.
Sujet(s)
Embolisation thérapeutique , Varices oesophagiennes et gastriques , Hémorragie gastro-intestinale , Hypertension portale , Humains , Mâle , Femelle , Varices oesophagiennes et gastriques/thérapie , Embolisation thérapeutique/méthodes , Hypertension portale/complications , Adulte d'âge moyen , Hémorragie gastro-intestinale/prévention et contrôle , Hémorragie gastro-intestinale/étiologie , Hémorragie gastro-intestinale/thérapie , Hémorragie gastro-intestinale/mortalité , Prévention secondaire/méthodes , Artère splénique , Adulte , Récidive , Résultat thérapeutique , Sujet âgéRÉSUMÉ
Ectopic varices are rare but potentially life-threatening conditions usually resulting from a combination of global portal hypertension and local occlusive components. As imaging, innovative devices, and interventional radiologic techniques evolve and are more widely adopted, interventional radiology is becoming essential in the management of ectopic varices. The interventional radiologist starts by diagnosing the underlying causes of portal hypertension and evaluating the afferent and efferent veins of ectopic varices with CT. If decompensated portal hypertension is causing ectopic varices, placement of a transjugular intrahepatic portosystemic shunt is considered the first-line treatment, although this treatment alone may not be effective in managing ectopic variceal bleeding because it may not sufficiently resolve focal mesenteric venous obstruction causing ectopic varices. Therefore, additional variceal embolization should be considered after placement of a transjugular intrahepatic portosystemic shunt. Retrograde transvenous obliteration can serve as a definitive treatment when the efferent vein connected to the systemic vein is accessible. Antegrade transvenous obliteration is a vital component of interventional radiologic management of ectopic varices because ectopic varices often exhibit complex anatomy and commonly lack catheterizable portosystemic shunts. Superficial veins of the portal venous system such as recanalized umbilical veins may provide safe access for antegrade transvenous obliteration. Given the absence of consensus and guidelines, a multidisciplinary team approach is essential for the individualized management of ectopic varices. Interventional radiologists must be knowledgeable about the anatomy and hemodynamic characteristics of ectopic varices based on CT images and be prepared to consider appropriate options for each specific situation. ©RSNA, 2024 Supplemental material is available for this article.
Sujet(s)
Hémorragie gastro-intestinale , Anastomose portosystémique intrahépatique par voie transjugulaire , Humains , Anastomose portosystémique intrahépatique par voie transjugulaire/méthodes , Hémorragie gastro-intestinale/imagerie diagnostique , Hémorragie gastro-intestinale/thérapie , Hémorragie gastro-intestinale/étiologie , Varices oesophagiennes et gastriques/imagerie diagnostique , Varices oesophagiennes et gastriques/thérapie , Hypertension portale/imagerie diagnostique , Hypertension portale/complications , Varices/imagerie diagnostique , Varices/thérapie , Radiographie interventionnelle/méthodes , Radiologie interventionnelle/méthodes , Embolisation thérapeutique/méthodes , Tomodensitométrie/méthodesRÉSUMÉ
Portal hypertension (PHT) is defined as an increase in pressure at the level of the portal vein above 5 mmHg, the most common cause being liver cirrhosis. Among the presinusoidal intrahepatic causes of PHT with portal venular involvement, what was traditionally known as idiopathic non-cirrhotic portal hypertension (NCIH) is described, with the requirements of excluding those patients who did not present PHT, as well as those with the presence of liver cirrhosis and thrombosis. portal venous vein (PVT). Currently, the diagnostic criteria for this entity have been reconsidered, and its name, being known as porto-sinusoidal vascular disease (PSVD), also does not exclude patients with PHT or the presence of underlying liver disease. Liver biopsy continues to be the gold standard for diagnosis. The clinical manifestations are derived from PHT and the management is similar to the complications that occur in patients with liver cirrhosis. The case of a male patient is presented who presents with symptoms of digestive bleeding, with findings of esophageal varices in upper endoscopy in addition to a study of viral, autoimmune liver disease and negative deposits, with a conclusive liver biopsy of porto-sinusoidal vascular disease.
Sujet(s)
Hémorragie gastro-intestinale , Hypertension portale , Humains , Mâle , Hémorragie gastro-intestinale/étiologie , Hémorragie gastro-intestinale/diagnostic , Hypertension portale/complications , Hypertension portale/étiologie , Hypertension portale/diagnostic , Veine porte , Adulte d'âge moyen , Maladie veno-occlusive hépatique/diagnostic , Maladie veno-occlusive hépatique/complicationsRÉSUMÉ
Porto-sinusoidal vascular disease (PSVD) is the medical diagnosis for a patient who has portal hypertension in the absence of cirrhosis on liver biopsy. There are several specific histologic findings for PSVD, including obliterative portal venopathy, nodular regenerative hyperplasia, and incomplete septal fibrosis. Epidemiologic reports vary widely among regions; PSVD comprises less than 10% of causes of portal hypertension in Western countries but incidence has been found to be as high as 48% in India. There is an expansive list of etiologies that have been reported to cause PSVD.
Sujet(s)
Hypertension portale , Humains , Hypertension portale/étiologie , Hypertension portale/diagnostic , Hypertension portale/complications , Hypertension portale/épidémiologie , Maladie veno-occlusive hépatique/étiologie , Maladie veno-occlusive hépatique/diagnostic , Veine porte/anatomopathologieRÉSUMÉ
Portopulmonary hypertension (POPH), hepatopulmonary syndrome, and hepatic hydrothorax constitute significant complications of portal hypertension, with important implications for management and liver transplantation (LT) candidacy. POPH is characterized by obstruction and remodeling of the pulmonary resistance arterial bed. Hepatopulmonary syndrome is the most common pulmonary vascular disorder, characterized by intrapulmonary vascular dilatations causing impaired gas exchange. LT may improve prognosis in select patients with POPH. LT is the only effective treatment of hepatopulmonary syndrome. Hepatic hydrothorax is defined as transudative pleural fluid accumulation that is not explained by primary cardiopulmonary or pleural disease. LT is the definitive cure for hepatic hydrothorax.
Sujet(s)
Syndrome hépatopulmonaire , Hydrothorax , Hypertension portale , Hypertension pulmonaire , Transplantation hépatique , Humains , Hypertension portale/étiologie , Hypertension portale/complications , Hypertension portale/physiopathologie , Syndrome hépatopulmonaire/étiologie , Syndrome hépatopulmonaire/physiopathologie , Syndrome hépatopulmonaire/thérapie , Hydrothorax/étiologie , Hydrothorax/thérapie , Hypertension pulmonaire/étiologie , Hypertension pulmonaire/physiopathologieRÉSUMÉ
In portal hypertension, acute variceal bleed is the cause of 2/3rd of all upper gastrointestinal bleeding episodes. It is a life-threatening emergency in patients with cirrhosis. Nonselective beta-blockers by decreasing the hepatic venous pressure gradient are the mainstay of medical therapy for the prevention of variceal bleeding and rebleeding. Evaluation of the severity of bleed, hemodynamic resuscitation, prophylactic antibiotic, and intravenous splanchnic vasoconstrictors should precede the endoscopy procedure. Endoscopic band ligation is the recommended endotherapy. Rescue transjugular intrahepatic port-systemic shunt (TIPS) is recommended for variceal bleed refractory to endotherapy. In patients with a high risk of failure of combined pharmacologic and endoscopic therapy, pre-emptive TIPS may improve the outcome. For gastric varices, "Sarin classification" is universally applied as it is simple and has therapeutic implication. For IGV1 and GOV2, injection cyanoacrylate glue is considered the endotherapy of choice. Endoscopic ultrasound is a useful modality in the management of gastric varices.
Sujet(s)
Varices oesophagiennes et gastriques , Hémorragie gastro-intestinale , Hypertension portale , Anastomose portosystémique intrahépatique par voie transjugulaire , Humains , Hypertension portale/thérapie , Hypertension portale/complications , Hémorragie gastro-intestinale/étiologie , Hémorragie gastro-intestinale/thérapie , Varices oesophagiennes et gastriques/thérapie , Varices oesophagiennes et gastriques/étiologie , Ligature , Antagonistes bêta-adrénergiques/usage thérapeutique , Cirrhose du foie/complicationsRÉSUMÉ
Patients with cirrhosis and clinically significant portal hypertension are at high risk of developing bacterial infections (BIs) that are the most common trigger of acute decompensation and acute-on-chronic liver failure. Furthermore, after decompensation, the risk of developing BIs further increases in an ominous vicious circle. BIs may be subtle, and they should be ruled out in all patients at admission and in case of deterioration. Timely administration of adequate empirical antibiotics is the cornerstone of treatment. Herein, we reviewed current evidences about pathogenesis, clinical implications and management of BIs in patients with cirrhosis and portal hypertension.
Sujet(s)
Antibactériens , Infections bactériennes , Hypertension portale , Cirrhose du foie , Humains , Hypertension portale/étiologie , Hypertension portale/complications , Cirrhose du foie/complications , Infections bactériennes/complications , Infections bactériennes/traitement médicamenteux , Antibactériens/usage thérapeutique , Insuffisance hépatique aigüe sur chronique/étiologie , Insuffisance hépatique aigüe sur chronique/thérapieRÉSUMÉ
Acute kidney injury (AKI) is a common complication among patients with decompensated cirrhosis and its development is associated with worse prognosis in terms of survival. Patients with decompensated cirrhosis may develop a unique type of AKI, known as hepatorenal syndrome (HRS-AKI), characterized by marked impairment of kidney function due to haemodynamic changes that occur in late stages of liver cirrhosis. Besides, patients with cirrhosis also may develop chronic alterations of kidney function (chronic kidney disease, CKD), the incidence of which is increasing markedly and may be associated with clinical complications. The aim of this review is to provide the reader with an update of the most relevant aspects of alterations of kidney function in patients with cirrhossi that may be useful for theri clinical practice.
Sujet(s)
Atteinte rénale aigüe , Syndrome hépatorénal , Hypertension portale , Cirrhose du foie , Humains , Hypertension portale/étiologie , Hypertension portale/physiopathologie , Hypertension portale/complications , Syndrome hépatorénal/étiologie , Syndrome hépatorénal/physiopathologie , Atteinte rénale aigüe/étiologie , Atteinte rénale aigüe/physiopathologie , Cirrhose du foie/complications , Cirrhose du foie/physiopathologie , Insuffisance rénale chronique/complications , Insuffisance rénale chronique/physiopathologieRÉSUMÉ
Portal hypertension has cerebral consequences via its causes and complications, namely hepatic encephalopathy (HE), a common and devastating brain disturbance caused by liver insufficiency and portosystemic shunting. The pathogenesis involves hyperammonemia and systemic inflammation. Symptoms are disturbed personality and reduced attention. HE is minimal or grades I to IV (coma). Bouts of HE are episodic and often recurrent. Initial treatment is of events that precipitated the episode and exclusion of nonhepatic causes. Specific anti-HE treatment is lactulose. By recurrence, rifaximin is add-on. Anti-HE treatment is efficacious also for prophylaxis, but emergence of HE marks advanced liver disease and a dismal prognosis.
Sujet(s)
Encéphalopathie hépatique , Hypertension portale , Lactulose , Encéphalopathie hépatique/étiologie , Encéphalopathie hépatique/physiopathologie , Humains , Hypertension portale/étiologie , Hypertension portale/complications , Hypertension portale/physiopathologie , Lactulose/usage thérapeutique , Rifaximine/usage thérapeutique , Agents gastro-intestinaux/usage thérapeutique , Hyperammoniémie/étiologie , Hyperammoniémie/complicationsRÉSUMÉ
RATIONAL: Congenital hepatic fibrosis (CHF) is a rare autosomal recessive genetic disease, which is often diagnosed in children and young adults. The clinical manifestations of CHF were lack of specificity, mainly including portal hypertension related symptoms and signs, and normal or mildly abnormal liver function. When no obvious varices are indicated under endoscope, it can easily lead to misdiagnosis or missed diagnosis. We report this case in the hope of raising awareness of this disease. PATIENT CONCERNS: A 31 years old male patient with major clinical manifestations of unexplained thrombocytopenia for 5 years. DIAGNOSES: Results of ultrasound, magnetic resonance imaging (MRI) and computed tomography portal venography (CTV) showed that patient had liver cirrhosis with portal hypertension and liver biopsy revealed CHF. INTERVENTION: Patient received ursodeoxycholic acid tablets, fuzheng huayu capsule, ganshuang granule, etc for liver protection treatment. OUTCOMES: The condition of patient stabilized after symptomatic treatment. Spleen resection will be considered during follow-up. LESSONS: This case reminds us that in case of patients with negative endoscopic evaluation, ultrasonic, computed tomography (CT) and MRI examination should be performed at the same time to determine whether patients have portal hypertension. When patients with normal or mildly abnormal liver function had unexplained liver cirrhosis complicated with portal hypertension, the possibility of CHF should be considered.
Sujet(s)
Varices oesophagiennes et gastriques , Cirrhose du foie , Humains , Mâle , Varices oesophagiennes et gastriques/étiologie , Varices oesophagiennes et gastriques/diagnostic , Adulte , Cirrhose du foie/complications , Hypertension portale/complications , Hypertension portale/diagnostic , Maladies génétiques congénitales/complications , Maladies génétiques congénitales/diagnostic , Imagerie par résonance magnétique/méthodes , Tomodensitométrie/méthodesRÉSUMÉ
BACKGROUND: The obesity epidemic has led to an increase in the proportion of patients with chronic liver disease due to metabolic associated steatosic liver disease and in the prevalence of obesity in patients with cirrhosis. Metabolic and bariatric surgery (MBS) has been proven to determine weight loss, obesity-related medical problems remission, and liver steatosis, inflammation, and fibrosis improvement. However, cirrhosis and portal hypertension are well-known risk factors for increased morbidity and mortality after surgery. The aim of this study is to evaluate the safety of MBS in patients with compensated advanced chronic liver disease (cALCD) and clinically significant portal hypertension (CSPH). MATERIAL AND METHODS: This is an international, multicentric, retrospective study on 63 individuals affected by obesity with cALCD and CSPH who underwent MBS in tertiary referral centers with experts hepatobiliary surgeons between January 2010 and October 2022. The primary endpoint was postoperative mortality at 90 days. The secondary endpoints included postoperative weight loss at last follow-up and postoperative complication rate. In addition, the authors performed subgroup analyses of Child-Pugh (A vs. B) score, MELD (≤9 vs. >9) score, and type of surgery. RESULTS: One patient (1.6%) experienced gastric leakage and mortality. There were three (5%) reported cases of portal vein thrombosis, two (3%) postoperative acute renal failure, and one (1.6%) postoperative encephalopathy. Child-Pugh score A resulted to be a protective factor for intraoperative bleeding requiring transfusion at univariate analysis (OR: 0.73, 95% CI: 0.55-0.97, P =0.046) but not at multivariate analysis. MELD>9 score and the type of surgery did not result to be a risk factor for any postoperative complication. CONCLUSION: MBS is safe in patients with cALCD and CSPH performed in tertiary bariatric referral centers with hepatobiliary expert surgeons. Larger, prospective studies with longer follow-up periods are needed to confirm these results.
Sujet(s)
Chirurgie bariatrique , Hypertension portale , Humains , Études rétrospectives , Femelle , Mâle , Chirurgie bariatrique/effets indésirables , Chirurgie bariatrique/méthodes , Adulte d'âge moyen , Hypertension portale/complications , Hypertension portale/chirurgie , Adulte , Études de faisabilité , Résultat thérapeutique , Complications postopératoires/épidémiologie , Complications postopératoires/étiologie , Maladie chronique , Sujet âgé , Maladies du foie/chirurgie , Maladies du foie/complicationsRÉSUMÉ
INTRODUCTION: There are many options for the reduction of portal hypertension (pH) in cirrhotic patients, but all the current ones have side effects. Probiotics are a new approach for ameliorating the hyperdynamic circulation of cirrhotic patients. The aim of this study is to measure the effect of probiotics on pH in cirrhosis for the first time. METHODS: A search was conducted across four electronic databases (PubMed, Scopus, Web of Science, Cochrane) for English-language records evaluating probiotic effects on pH in cirrhotic patients. Quality assessment used the Cochrane Collaboration's tool, employing a random-effects model in statistical analysis with Stata software version 1. RESULTS: A search yielded 1,251 articles, which were narrowed down to 5 through screening. These studies, involving 158 participants across Canada, India, Spain, and Russia, focused on probiotic interventions in cirrhotic patients. Meta-analysis of two RCTs (66 participants) indicated a significant decrease in hepatic venous pressure gradient (HVPG) (SMD: -0.60 [-1.09, -0.12]). In single-arm analysis, four studies (58 participants) showed a substantial reduction in HVPG with probiotic use compared to the control (SMD: -2.55 [-3.42, -1.68]). CONCLUSION: In summary, it showcased a notable reduction in HVPG compared to the control group, indicating a potential advantage of probiotics in decreasing pH in cirrhotic patients. Further research with larger samples and robust designs is warranted.
Sujet(s)
Hypertension portale , Cirrhose du foie , Probiotiques , Humains , Hypertension portale/complications , Probiotiques/usage thérapeutique , Cirrhose du foie/complicationsRÉSUMÉ
BACKGROUND AND AIMS: Wilson's disease may progress to cirrhosis and clinically significant portal hypertension (CSPH). We aimed to assess the prevalence and prognostic impact of CSPH-related features on hepatic decompensation and transplant-free survival in patients with Wilson's disease. METHODS AND RESULTS: About 137 patients with Wilson's disease (Leipzig score ≥4), followed for a median observation period of 9.0 (3.9-17.7) years at the Vienna General Hospital, were included in this retrospective study. Overall, 49 (35.8%) developed features of CSPH: 14 (10.2%) varices, 40 (29.2%) splenomegaly, 20 (14.6%) ascites, 18 (13.1%) hepatic encephalopathy and 3 (2.2%) experienced acute variceal bleeding. Overall, 8 (5.8%) patients died, including three deaths caused by CSPH-related complications. Within 10 years, compensated patients with features of CSPH developed more decompensation events (8.3% vs. 1.5% in patients without CSPH, p = 0.3) and had worse transplant-free-survival (91.7% vs. 98.6%), which further declined in patients with hepatic decompensation (26.7%, log-rank: p < 0.0001). Patients with liver stiffness <15 kPa and normal platelets (≥150 G/L) were less likely to decompensate within 10 years (2.6% vs. 8.4%, p = 0.002) and had a better 10-year transplant-free-survival (97.7% vs. 83.9%, p = 0.006). CONCLUSIONS: Patients with Wilson's disease developing features of CSPH are at an increased risk for hepatic decompensation and liver-related mortality, warranting for regular screening and timely initiation of effective CSPH-directed treatments.
Sujet(s)
Dégénérescence hépatolenticulaire , Hypertension portale , Humains , Hypertension portale/étiologie , Hypertension portale/complications , Hypertension portale/mortalité , Dégénérescence hépatolenticulaire/mortalité , Dégénérescence hépatolenticulaire/complications , Dégénérescence hépatolenticulaire/physiopathologie , Mâle , Femelle , Études rétrospectives , Pronostic , Adulte , Adolescent , Jeune adulte , Cirrhose du foie/complications , Cirrhose du foie/mortalité , Varices oesophagiennes et gastriques/étiologie , Enfant , Adulte d'âge moyen , Hémorragie gastro-intestinale/étiologie , Encéphalopathie hépatique/étiologie , Autriche/épidémiologie , Évolution de la maladie , Transplantation hépatiqueRÉSUMÉ
BACKGROUND: Portal hypertension (PHT) has been proven to be closely related to the development of hepatocellular carcinoma (HCC). Whether PHT before liver transplantation (LT) will affect the recurrence of HCC is not clear. METHODS: 110 patients with depressurization of the portal vein (DPV) operations (Transjugular Intrahepatic Portosystemic Shunt-TIPS, surgical portosystemic shunt or/and splenectomy) before LT from a HCC LT cohort, matched with 330 preoperative non-DPV patients; this constituted a nested case-control study. Subgroup analysis was based on the order of DPV before or after the occurrence of HCC. RESULTS: The incidence of acute kidney injury and intra-abdominal bleeding after LT in the DPV group was significantly higher than that in non-DPV group. The 5-year survival rates in the DPV and non-DPV group were 83.4% and 82.7% respectively (P = 0.930). In subgroup analysis, patients in the DPV prior to HCC subgroup may have a lower recurrence rate (4.7% vs.16.8%, P = 0.045) and a higher tumor free survival rate (88.9% vs.74.4%, P = 0.044) after LT under the up-to-date TNMI-II stage, while in TNM III stage, there was no difference for DPV prior to HCC subgroup compared with the DPV after HCC subgroup or the non-DPV group. CONCLUSION: Compared with DPV after HCC, DPV treatment before HCC can reduce the recurrence rate of HCC after early transplantation (TNM I-II). DPV before LT can reduce the recurrence of early HCC.